MCM6 and MCM7 monoclonal antibodies and methods for their...

Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Structurally-modified antibody – immunoglobulin – or fragment...

Reexamination Certificate

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

C435S338000, C435S007230, C530S388800

Reexamination Certificate

active

07632498

ABSTRACT:
Compositions and methods for diagnosing high-grade cervical disease in a patient sample are provided. The compositions include novel monoclonal antibodies, and variants and fragments thereof, that specifically bind to MCM6 or MCM7. Monoclonal antibodies having the binding characteristics of an MCM6 or MCM7 antibody of the invention are further provided. Hybridoma cell lines that produce an MCM6 or MCM7 monoclonal antibody of the invention are also disclosed herein. The compositions find use in practicing methods for diagnosing high-grade cervical disease comprising detecting overexpression of MCM6, MCM7, or both MCM6 and MCM7 in a cervical sample from a patient. Kits for practicing the methods of the invention are further provided. Polypeptides comprising the amino acid sequence for an MCM6 or an MCM7 epitope and methods of using these polypeptides in the production of antibodies are also encompassed by the present invention.

REFERENCES:
patent: WO 2005/095964 (2005-10-01), None
Fundamental Immunology 242 (William E. Paul, M.D. ed., 3d ed. 1993).
Lederman et al (Molecular Immunology 28:1171-1181, 1991).
Li et al (Proc. Natl. Acad. Sci. USA 77:3211-3214, 1980).
Freeman et al. (Clin. Can. Res. 5:2121-2132 (1999)).
Williams et al. (PNAS 95:14932-14937 (1998)).
Hiraiwa et al. (Int. J. Cancer (Pred. Oncol.) 74:180-184 (1997)).
Neomarkers data sheet for MCM7 (Lab Vision pp. 1-2).
CDC47/ MCM7 Ab2 data sheet (Lab Vision pp. 1-3).
Campbell et al, Biology, 5th ed. p. 856, 1999.
Brake, T., et al., “Comparative Analysis of Cervical Cancer in Women and in a Human Papillomavirus-Transgenic Mouse Model: Identification ofMinichromosome Maintenance Protein 7as an Informative Biomarker for Human Cervical Cancer”,Cancer Research, Dec. 2003, pp. 8173-8180, vol. 63.
Grunicke, H.H., et al., “Role and Characterization of Protein Kinase C Isoforms Implicated in the Transcriptional Activation of Cyclin D1 by Transforming HA-RAS”,Cell Biology International, 2001, A16-A17, vol. 25.
Heidebrecht, H.J., et al. “Ki-Mcm6 a Monoclonal Antibody Specific for the Human Minichromosome Maintenance Protein 6 (Mcm6)”,Joint Annual Meeting, 2000, p. 406, University of Kiel and University ofHamburg, Germany.
Helfenstein, A., et al., “Minichromosome Maintenance Protein (MCM6) in Low-Grade Chondrosarcoma”,Am. J. Clin. Pathology, 2004, pp. 912-918, vol. 122.
Ishimi Y., et al., “Enhanced Expression of Mcm Proteins in Cancer Cells Derived from Uterine Cervix”,Eur. J. Biochem., Feb. 2003, pp. 1089-1101, vol. 270.
Malinowski D.P., “Molecular diagnostic Assays for Cervical Neoplasia: Emerging Markers for the Detection of High-Grade Cervical Disease”,BioTechniques, Apr. 2005, pp. 17-23, vol. 38.
Schrader, C., et al., “Minichromosome Maintenance Protein 6, a Proliferation Marker Superior to Ki-67 and Independent Predictor of Survival in Patients with Mantle Cell Lymphoma”,British Journal of Cancer, 2005, pp. 939-945, vol. 93.

LandOfFree

Say what you really think

Search LandOfFree.com for the USA inventors and patents. Rate them and share your experience with other people.

Rating

MCM6 and MCM7 monoclonal antibodies and methods for their... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with MCM6 and MCM7 monoclonal antibodies and methods for their..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and MCM6 and MCM7 monoclonal antibodies and methods for their... will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFUS-PAI-O-4091531

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.